Core Viewpoint - The article discusses the approval of a biodegradable PFO closure device by the National Medical Products Administration, highlighting its innovative design and potential market growth in the field of structural heart disease interventions [2][5]. Market and Industry Overview - The biodegradable PFO closure device market is in its early commercialization stage, with a projected market size of approximately $161 million in 2025, expected to grow to $254 million by 2032, reflecting a compound annual growth rate (CAGR) of about 6.7% from 2026 to 2032, which is higher than the overall PFO closure device market growth of 5.6% [5]. - China is identified as a significant growth market for this sector, with nearly 60,000 PFO intervention surgeries performed in 2023, ranking among the top globally [5]. Product Introduction - The ConBrella™ biodegradable closure system consists of a closure device, delivery system, loader, and auxiliary components, designed for patients aged 18 to 60 with a history of unexplained strokes and specific anatomical features [4][6]. Competitive Landscape - The article outlines several competing products in the biodegradable PFO closure device market, including: - **Memosorb**: Features a patented design for stability and effective closure [10]. - **Pansy**: A self-expanding device with improved biocompatibility and a focus on safety [11]. - **IrisFIT**: A partially biodegradable device designed to reduce thrombus formation [12]. - **BioSTAR**: The first bioabsorbable closure device, designed for ASD and PFO closure [16]. - **Double Umbrella**: A fully biodegradable device with a unique design for effective closure [17]. - **Chinese Lantern**: A device utilizing a unique folding mechanism for closure [18]. Company Profile - Wuyou Jump Medical Technology (Shenzhen) Co., Ltd. was established in June 2021, focusing on innovative solutions for structural heart disease interventions, particularly PFO [19][21].

Core Viewpoint - The article highlights the advancements in biodegradable septal occluders in China, particularly focusing on the recent approval of innovative products by companies like Shanghai Jinkui Medical and Lepu Medical, marking significant progress in the treatment of atrial septal defects (ASD) [2][3]. R&D Background - Atrial septal defect (ASD) is a common congenital heart defect, accounting for approximately 10% of all congenital heart diseases and 20%-30% of adult congenital heart diseases [3]. - The standard treatment for ASD involves the implantation of septal occluders, which traditionally are made of metal and can lead to complications such as nickel ion release and thrombosis [4]. Company Product Introduction - Shanghai Jinkui Medical has developed a biodegradable septal occluder, which is expected to enhance the domestic high-end innovation landscape in the field of ASD treatment [2]. - The Pansy biodegradable PFO occluder features improved shape recovery, biocompatibility, and a reasonable absorption cycle, having completed prospective multi-center clinical trials [6][11]. Product Features - The Pansy occluder is designed to provide sufficient support for the repair of the defect while being gradually absorbed by the body, with degradation products being harmless [7]. - The Mallow® single-rivet septal occluder is a domestically innovative product that is suitable for various types of ASD interventions [10]. Market Trends - The number of ASD occlusion procedures in China has shown a compound annual growth rate (CAGR) of 32.17%, increasing from 33,200 cases in 2021 to 58,000 cases in 2023 [13]. - The market for septal occluders in China is projected to grow from 155 million RMB in 2017 to 382 million RMB by 2027, with a CAGR of 6.4% from 2021 to 2027 [13]. Company Overview - Jinkui Medical, established in 2003, specializes in the R&D, production, and sales of cardiovascular interventional high-value consumables, with several innovative products already approved for market [28].